Komori
Nitto Denko (6988) · RiskFirst stated

Cost and Pricing Burden of Capacity Expansion in Contract Manufacturing of Nucleic Acid Drugs

First written in FY2018-Q2. . Latest entry: FY2018-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Profit Pressure from Expanded Nucleic Acid Drug Contract Manufacturing Capacity and Pricing AdjustmentsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2018-Q2First statedAnnual report

    「Although revenue increased year on year, profit growth remained sluggish due in part to higher costs associated with the latest capacity expansion investment and the impact of pricing adjustments for certain projects.」

    Higher costs associated with expanding contract manufacturing capacity for nucleic acid drugs and pricing adjustments on certain projects squeezed profit, resulting in sluggish profit growth.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Nitto Denko's next results are scheduled for 2026-10-27. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Cost and Pricing Burden of Capacity Expansion in Contract Manufacturing of Nucleic Acid Drugs | NITTO DENKO CORPORATION (6988) | Komori